Extra JM, Espie M, Calvo F, Ferme C, Mignot L, Marty M (1990) Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 25(4):299–303

Article  PubMed  CAS  Google Scholar 

Oh PJ, Lee JR, Kim SK, Kim JH (2020) Changes in chemotherapy-induced peripheral neuropathy, disturbance in activities of daily living, and depression following chemotherapy in patients with colorectal cancer: a prospective study. Eur J Oncol Nurs 44:101676

Article  PubMed  Google Scholar 

Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M et al (2006) OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer–a GERCOR study. J Clin Oncol 24(3):394–400

Article  PubMed  CAS  Google Scholar 

Lersch C, Schmelz R, Eckel F, Erdmann J, Mayr M, Schulte-Frohlinde E et al (2002) Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer. Clin Colorectal Cancer 2(1):54–58

Article  PubMed  CAS  Google Scholar 

Penz M, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger W, Scheithauer W (2001) Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy. Ann Oncol 12(3):421–422

Article  PubMed  CAS  Google Scholar 

Cascinu S, Cordella L, Del Ferro E, Fronzoni M, Catalano G (1995) Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. J Clin Oncol 13(1):26–32

Article  PubMed  CAS  Google Scholar 

Cascinu S, Catalano V, Cordella L, Labianca R, Giordani P, Baldelli AM et al (2002) Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 20(16):3478–3483

Article  PubMed  CAS  Google Scholar 

Gedlicka C, Scheithauer W, Schüll B, Kornek GV (2002) Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid. J Clin Oncol 20(15):3359–3361

Article  PubMed  CAS  Google Scholar 

Mitchell PL, Goldstein D, Michael M, Beale P, Friedlander M, Zalcberg J et al (2006) Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity. Clin Colorectal Cancer 6(2):146–151

Article  PubMed  CAS  Google Scholar 

Pfeiffer P, Lustberg M, Näsström J, Carlsson S, Persson A, Nagahama F et al (2022) Calmangafodipir for prevention of oxaliplatin-induced peripheral neuropathy: two placebo-controlled, randomized phase 3 studies (POLAR-A/POLAR-M). JNCI Cancer Spectr 6(6):pkac075

Article  PubMed  PubMed Central  Google Scholar 

Agence nationale de sécurité du médicament et des produits de santé (ANSM). https://base-donnees-publique.medicaments.gouv.fr/. Accessed 23 Aug 2024

Breedis C, Young G (1954) The blood supply of neoplasms in the liver. Am J Pathol 30(5):969–977

PubMed  PubMed Central  CAS  Google Scholar 

Kingham TP, D’Angelica M, Kemeny NE (2010) Role of intra-arterial hepatic chemotherapy in the treatment of colorectal cancer metastases. J Surg Oncol 102(8):988–995

Article  PubMed  Google Scholar 

Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ et al (2006) Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 24(9):1395–1403

Article  PubMed  CAS  Google Scholar 

Mocellin S, Pasquali S, Nitti D (2009) Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer. Cochrane Database Syst Rev 3:CD007823

Google Scholar 

Ducreux M, Ychou M, Laplanche A, Gamelin E, Lasser P, Husseini F et al (2005) Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 23(22):4881–4887

Article  PubMed  CAS  Google Scholar 

Boige V, Malka D, Elias D, Castaing M, De Baere T, Goere D et al (2008) Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol 15(1):219–226

Article  PubMed  Google Scholar 

Malka D, Boige V, Faron M, Caramella C, Boucher E, Rivera P et al (2012) Hepatic arterial infusion (HAI) of oxaliplatin plus intravenous (IV) fluorouracil (FU), leucovorin (LV) and cetuximab for first-line treatment of unresectable colorectal liver metastases (CRLM): final results of a multicenter phase 2 study (CHOICE). Ann Oncol 1(23):ix98

Google Scholar 

Lévi FA, Boige V, Hebbar M, Smith D, Lepère C, Focan C et al (2016) Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV. Ann Oncol 27(2):267–274

Article  PubMed  Google Scholar 

Gelli M, Ewald J, Tanguy ML, Passot G, Quenet F, Touchefeu Y et al (2023) Postoperative hepatic arterial chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a multicenter randomized phase II trial (PRODIGE 43 - PACHA-01). JCO 41(16_suppl):3515–3515

Article  Google Scholar 

Guthoff I, Lotspeich E, Fester C, Wallin I, Schatz M, Ehrsson H et al (2003) Hepatic artery infusion using oxaliplatin in combination with 5-fluorouracil, folinic acid and mitomycin C: oxaliplatin pharmacokinetics and feasibility. Anticancer Res 23(6D):5203–5208

PubMed  CAS  Google Scholar 

Dzodic R, Gomez-Abuin G, Rougier P, Bonnay M, Ardouin P, Gouyette A et al (2004) Pharmacokinetic advantage of intra-arterial hepatic oxaliplatin administration: comparative results with cisplatin using a rabbit VX2 tumor model. Anticancer drugs 15(6):647–650

Article  PubMed  CAS  Google Scholar 

Pernot S, Pellerin O, Mineur L, Monterymard C, Smith D, Lapuyade B et al (2022) Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/− irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49. Dig Liver Dis 54(3):324–330

Article  PubMed  CAS  Google Scholar 

Ducreux M, Malka D, Mendiboure J, Etienne PL, Texereau P, Auby D et al (2011) Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000–05): an open-label, randomised, phase 3 trial. Lancet Oncol 12(11):1032–1044

Article  PubMed  CAS  Google Scholar 

Common terminology criteria for adverse events (CTCAE) | Protocol development | CTEP [Internet]. [cited 2023 Oct 28]. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm

Caussanel JP, Lévi F, Brienza S, Misset JL, Itzhaki M, Adam R et al (1990) Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst 82(12):1046–1050

Article  PubMed  CAS  Google Scholar 

Pulvers JN, Marx G (2017) Factors associated with the development and severity of oxaliplatin-induced peripheral neuropathy: a systematic review. Asia Pac J Clin Oncol 13(6):345–355

Article  PubMed  Google Scholar 

Ehrsson H, Wallin I, Yachnin J (2002) Pharmacokinetics of oxaliplatin in humans. Med Oncol 19(4):261–265

Article  PubMed  CAS  Google Scholar 

Alberti P, Rossi E, Cornblath DR, Merkies ISJ, Postma TJ, Frigeni B et al (2014) Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. Ann Oncol 25(1):257–264

Article  PubMed  CAS  Google Scholar 

Postma TJ, Heimans JJ, Muller MJ, Ossenkoppele GJ, Vermorken JB, Aaronson NK (1998) Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 9(7):739–744

Article  PubMed  CAS  Google Scholar 

Stephens RJ, Hopwood P, Girling DJ, Machin D (1997) Randomized trials with quality of life endpoints: are doctors’ ratings of patients’ physical symptoms interchangeable with patients’ self-ratings? Qual Life Res 6(3):225–236

Article  PubMed  CAS  Google Scholar 

Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K et al (2009) Feasibility and validity of the patient neurotoxicity questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Support Care Cancer 17(12):1483–1491

Article  PubMed